Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer

Bibliographic Details
Title: Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer
Authors: Andras Piffko, Benedikt Asey, Lasse Dührsen, Inka Ristow, Johannes Salamon, Harriet Wikman, Cecile L. Maire, Katrin Lamszus, Manfred Westphal, Thomas Sauvigny, Malte Mohme
Source: Frontiers in Oncology, Vol 12 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: NSCLC, metastasis, brain metastasis, survival, resectable, surgery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Non-small cell lung cancer (NSCLC) is currently the leading cause of cancer-related death worldwide, and the incidence of brain metastases (BM) in NSCLC patients is continuously increasing. The recent improvements of systemic treatment in NSCLC necessitate continuous updates on prognostic subgroups and factors determining overall survival (OS). In order to improve clinical decision-making in tumor boards, we investigated the clinical determinants affecting survival in patients with resectable NSCLC BM. A retrospective analysis was conducted of NSCLC patients with surgically resectable BM treated in our institution between 01/2015 and 12/2020. The relevant clinical factors affecting survival identified by univariate analysis were included in a multivariate logistic regression model. Overall, 264 patients were identified, with a mean age of 62.39 ± 9.98 years at the initial diagnosis of NSCLC BM and OS of 23.22 ± 1.71 months. The factors that significantly affected OS from the time of primary tumor diagnosis included the systemic metastatic load (median: 28.40 ± 4.82 vs. 40.93 ± 11.18 months, p = 0.021) as well as a number of BM
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.951805/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2022.951805
Access URL: https://doaj.org/article/6d3671d62d0a4be786863941023d525f
Accession Number: edsdoj.6d3671d62d0a4be786863941023d525f
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2022.951805
Published in:Frontiers in Oncology
Language:English